Aspen Neuroscience (ASPE) raises $140.6 million in Nasdaq IPO at $15
As seen on the 24/7 Wall St. homepage on October 30, 2026.
Aspen Neuroscience prices Nasdaq IPO at $15, raising $140.6 million
Aspen Neuroscience priced at $15 a share, raising about $140.6 million for its cell therapy work in Parkinson's disease. Leerink, Piper Sandler, Stifel, UBS and Oppenheimer ran the book, and trading begins on Nasdaq with the clinical pipeline now funded in public view.
Continue ReadingShow less
Aspen Neuroscience raised $140.6 million in its Nasdaq IPO, putting a concrete dollar figure behind its clinical ambitions in Parkinson's disease cell therapy, a field that demands significant capital before any revenue arrives.
Five banks shared the bookrunning duties: Leerink, Piper Sandler, Stifel, UBS, and Oppenheimer. That breadth of institutional coverage signals an effort to build a diversified shareholder base from day one, spreading the stock across different investor networks.
Sponsored
With trading now open, the proceeds are earmarked to fund the clinical pipeline. For investors, the key question going forward is how far $140.6 million carries the program through its development milestones before the company would need to return to the market for additional financing.
Cell therapy approaches to Parkinson's disease remain early-stage across the industry, meaning Aspen's public debut places the pipeline under a new level of scrutiny from analysts and shareholders who will track every data readout. The SEC filing is the primary public document detailing the specifics of the offering and the company's financial position.
Mentioned: ASPE